You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,796,299


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,796,299
Title:NK1 antagonists
Abstract: A NK.sub.1 antagonist having the formula (I), ##STR00001## wherein Ar.sup.1 and Ar.sup.2 are optionally substituted phenyl or heteroaryl, X.sup.1 is an ether, thio or imino linkage, R.sup.4 and R.sup.5 are not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.
Inventor(s): Paliwal; Sunil (Monroe Township, NJ), Reichard; Gregory A. (Ann Arbor, MI), Wang; Cheng (Summit, NJ), Xiao; Dong (Warren, NJ), Tsui; Hon-Chung (East Brunswick, NJ), Shih; Neng-Yang (Warren, NJ), Arredondo; Juan D. (Montclair, NJ), Wrobleski; Michelle Laci (Whitehouse Station, NJ), Palani; Anandan (Bridgewater, NJ)
Assignee: OPKO Health, Inc. (Miami, FL)
Application Number:13/625,799
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 8,796,299

Introduction

United States Patent 8,796,299, hereafter referred to as the '299 patent, is a patent that has been granted by the United States Patent and Trademark Office (USPTO). To provide a comprehensive analysis, we need to delve into several key aspects, including the patent's claims, its scope, and the broader patent landscape it operates within.

Patent Overview

Invention Description

The '299 patent typically describes an invention that addresses a specific problem or improves upon existing technology. The patent document will outline the background of the invention, the summary of the invention, and a detailed description of the preferred embodiments.

Claims

The claims section is the most critical part of a patent as it defines the scope of the invention. Claims are statements that define the boundaries of what the inventor considers to be their invention. There are two main types of claims: independent claims and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit an independent claim.

Claim Analysis

Independent Claims

Independent claims in the '299 patent will outline the broadest scope of the invention. These claims are crucial because they define the outer limits of what is considered novel and non-obvious.

Dependent Claims

Dependent claims narrow down the scope of the independent claims by adding additional limitations. These claims are often used to provide a fallback position in case the broader independent claims are found invalid.

Scope of the Patent

Patent Scope and Breadth

The scope of the '299 patent is determined by the language of its claims. The broader the claims, the wider the scope of protection. However, broader claims are also more susceptible to challenges based on prior art or obviousness.

Claim Construction

Claim construction is the process of interpreting the meaning of the claims. This is often a critical issue in patent litigation, as the interpretation of claim terms can significantly affect the scope of the patent. Courts use various tools, such as the claim language itself, the specification, and the prosecution history, to construe the claims[5].

Patent Landscape

Prior Art and Obviousness

The '299 patent must have been found to be novel and non-obvious over the prior art to be granted. Prior art includes all publicly available information before the patent's filing date. The patent office and courts assess whether the invention would have been obvious to a person of ordinary skill in the relevant field at the time of the invention[4].

Continuations and Family Members

Like the patents discussed in the Cellect case, the '299 patent might be part of a family of patents, including continuations, continuations-in-part, or divisional applications. These related patents can impact the overall patent landscape and the validity of the claims[1].

Post-Grant Proceedings

Inter Partes Review (IPR)

The Leahy-Smith America Invents Act (AIA) introduced several post-grant proceedings, including Inter Partes Review (IPR), which allows third parties to challenge the validity of granted patents before the Patent Trial and Appeal Board (PTAB). The '299 patent could potentially be subject to such proceedings if a challenger argues that the claims are invalid based on prior art or other grounds[4].

Patent Trial and Appeal Board (PTAB)

PTAB plays a crucial role in post-grant proceedings, including IPR, Post-Grant Review (PGR), and Covered Business Method (CBM) review. These proceedings can significantly impact the validity and scope of the '299 patent if challenged[4].

Economic and Statistical Context

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents granted between 1976 and 2014. This dataset can offer insights into trends and patterns in patent claims, which might be relevant when analyzing the '299 patent's claims and scope[3].

Legal and Policy Considerations

Abstract Ideas and Patent Eligibility

The '299 patent must comply with Section 101 of the Patent Act, which requires that the invention be a new and useful process, machine, manufacture, or composition of matter. The Supreme Court's "Alice" test is used to determine whether claims are directed to abstract ideas, which are not patentable[5].

Small Claims Patent Court

There have been discussions and studies on the feasibility of a small claims patent court, which could potentially impact how disputes related to the '299 patent are resolved. Such a court could provide a more streamlined and cost-effective way to handle patent disputes, especially for smaller entities[2].

Case Law and Precedents

Federal Circuit Decisions

Decisions from the Federal Circuit, such as those in the Contour IP Holding LLC v. GoPro, Inc. case, can provide guidance on how to interpret and apply patent laws, including claim construction and patent eligibility. These precedents are crucial in understanding the legal landscape surrounding the '299 patent[5].

Key Takeaways

  • Claims Analysis: The claims of the '299 patent define its scope and are critical in determining its validity and enforceability.
  • Patent Landscape: The patent's position within its family and the broader patent landscape can affect its validity and scope.
  • Post-Grant Proceedings: The '299 patent could be subject to IPR or other post-grant proceedings, which can challenge its validity.
  • Legal and Policy Considerations: Compliance with Section 101 and other legal requirements is essential for the patent's validity.
  • Economic Context: Understanding trends in patent claims through datasets can provide valuable insights.

FAQs

Q1: What is the significance of independent claims in a patent? Independent claims define the broadest scope of the invention and are crucial in determining the patent's validity and enforceability.

Q2: How does the Patent Trial and Appeal Board (PTAB) impact patents? PTAB can hear challenges to the validity of patents through post-grant proceedings like IPR, PGR, and CBM review, which can affect the patent's scope and validity.

Q3: What is the "Alice" test, and why is it important? The "Alice" test is a two-step process used to determine whether patent claims are directed to abstract ideas, which are not patentable. It is crucial in assessing patent eligibility under Section 101 of the Patent Act.

Q4: How can a small claims patent court impact patent disputes? A small claims patent court could provide a more streamlined and cost-effective way to handle patent disputes, especially beneficial for smaller entities.

Q5: Why is claim construction important in patent litigation? Claim construction is important because it determines the meaning of the claims, which can significantly affect the scope of the patent and its enforceability.

Sources

  1. In re Cellect, LLC, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. U.S. Patent Small Claims Court, Administrative Conference of the United States.
  3. Patent Claims Research Dataset, United States Patent and Trademark Office.
  4. The Patent Trial and Appeal Board and Inter Partes Review, Congressional Research Service, June 29, 2023.
  5. Contour IP Holding LLC v. GoPro, Inc., United States Court of Appeals for the Federal Circuit, September 9, 2024.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,796,299

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,796,299

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1463716 ⤷  Subscribe 300895 Netherlands ⤷  Subscribe
European Patent Office 1463716 ⤷  Subscribe CR 2017 00041 Denmark ⤷  Subscribe
European Patent Office 1463716 ⤷  Subscribe PA2017032 Lithuania ⤷  Subscribe
European Patent Office 1463716 ⤷  Subscribe 122017000080 Germany ⤷  Subscribe
European Patent Office 1463716 ⤷  Subscribe LUC00043 Luxembourg ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.